What is Leerink Partnrs' Forecast for LENZ Q1 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for LENZ Therapeutics in a research note issued to investors on Wednesday, March 19th. Leerink Partnrs analyst M. Goodman expects that the company will post earnings of ($0.53) per share for the quarter. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics' Q2 2025 earnings at ($0.62) EPS and Q4 2025 earnings at ($0.83) EPS.

A number of other brokerages also recently issued reports on LENZ. TD Cowen began coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They set a "buy" rating and a $60.00 price target on the stock. Citigroup increased their target price on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, LENZ Therapeutics has a consensus rating of "Buy" and an average target price of $41.67.

LENZ Therapeutics Stock Up 1.7 %

Shares of LENZ Therapeutics stock traded up $0.44 during trading on Monday, reaching $26.53. The company's stock had a trading volume of 88,675 shares, compared to its average volume of 166,747. LENZ Therapeutics has a 52 week low of $14.42 and a 52 week high of $38.93. The firm has a market cap of $730.72 million, a PE ratio of -5.56 and a beta of 0.58. The business's 50-day moving average price is $24.37 and its 200-day moving average price is $27.11.

Remove Ads

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04).

Institutional Investors Weigh In On LENZ Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LENZ. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of LENZ Therapeutics during the 4th quarter worth $29,000. SG Americas Securities LLC grew its position in LENZ Therapeutics by 20.7% in the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock valued at $158,000 after acquiring an additional 935 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in LENZ Therapeutics by 14.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company's stock worth $229,000 after acquiring an additional 1,005 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of LENZ Therapeutics by 6.2% in the fourth quarter. Rhumbline Advisers now owns 18,754 shares of the company's stock worth $541,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after purchasing an additional 1,151 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.